|Peregrine Completes Lung Cancer Trial; Publication of SANUWAVE, dermaPACE study bumps shares 20% higher|
|By Staff and Wire Reports|
|Wednesday, 12 October 2011 18:50|
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the completion of enrollment and randomization of 121 patients in a double-blind, placebo-controlled Phase II trial evaluating bavituximab in combination with docetaxel in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Bavituximab is a phosphatidylserine (PS)-targeting monoclonal antibody with broad therapeutic potential also being evaluated in randomized Phase II trials for front-line NSCLC, pancreatic cancer, and hepatitis C virus (HCV) infection as well as in several investigator-sponsored trials (ISTs) in additional oncology indications.
"Completing patient enrollment in three randomized Phase II trials over the last month sets the stage for reporting early results from all three trials over the coming months. We look forward to evaluating and reporting interim data from an earlier completed randomized Phase II trial in front-line NSCLC and data from an HCV study later this year as we await unblinding data from this second-line NSCLC trial in the first half of next year," said Steven W. King, president and chief executive officer of Peregrine. "In our prior Phase II trials, we have seen encouraging tumor response data, which have correlated with promising survival for patients treated with bavituximab in combination with chemotherapy. This latest trial's rigorous design is intended to determine if bavituximab may improve tumor response rates when given in combination with the commonly used second line chemotherapy treatment docetaxel.
Unfortunately treatment with docetaxel alone is expected to result in less than a 6%1 tumor response rate, but since docetaxel increases exposure of bavituximab's PS target, we believe the combination has a good chance to improve on these results and hopefully improve overall survival for patients who have already failed a prior treatment for this deadly form of cancer. We greatly appreciate the patients and investigators who have participated in our studies and our dedicated team at Peregrine working hard to advance our multiple Phase II trials."
Shares of SANUWAVE Health Inc (OTC:SNWV) rose 20.9% to $2.14 +0.37 after the company announced publication of research which investigated the molecular changes of dermaPACE extracorporeal shock wave technology (ESWT) compared with hyperbaric oxygen therapy (HBOT) in diabetic foot ulcers.
The study, titled Molecular Changes in Diabetic Foot Ulcers, by Ching-Jen Wang, M.D. of the Department of Orthopedic Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine in Kaohsiung, Taiwan, appeared in the online edition of the European peer-reviewed journal Diabetes Research and Clinical Practice as an ePublication ahead of print.
dermaPACE showed statistically significant increases in angiogenic and tissue regenerative molecular changes over HBOT in diabetic foot ulcers. dermaPACE demonstrated significant increases in angiogenesis (vWF, VEGF and eNOS) and cell proliferation (PCNA and EGF) and decreases in cell apoptosis (TUNEL), leading to tissue regeneration and wound repair (p<0.05), whereas the molecular changes after HBOT were not statistically significant.
The study consisted of 39 patients (44 ulcers) in the ESWT group and 38 patients (40 ulcers) in the HBOT group, with similar demographic characteristics. The ESWT group received dermaPACE procedures twice per week for a total of six procedures over three weeks. The HBOT group received hyperbaric oxygen therapy daily for a total of 20 treatments, each lasting 90 minutes. Biopsies were performed from the periphery of the ulcer before and after treatment.
Some recent trading activity prompted officials to look into the activities of one market maker in particular after Tuesday's session. It is unclear if the situation has been resolved, but there are definintely eyeballs monitoring the trading activities of the firm and trading action seemed to go much more smoothly on Wednesday.
Affymetrix®, Inc. (NASDAQ:AFFX) today announced at the ICHG/ASHG annual conference in Montreal, the worldwide launch of the Axiom® Genome-Wide Pan-African Array, the first commercial product to maximize genomic coverage of both common and rare alleles in populations of African ancestry, including West African, East African, and African American.
Anavex Life Sciences Corp. (OTCBB: AVXL) today announced the appointment of Dr. George Tidmarsh as director, and his engagement to act as an executive director.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 18th Annual Newsmakers in the Biotech Industry conference in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s oncology pipeline on Friday, October 21 at 9:00 a.m. (ET).
Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that results of the PREVENT-SCD trial, published in the journal Clinical Research in Cardiology, reinforce the value of the Microvolt T-Wave Alternans™ (MTWA) test in identifying patients at risk of Sudden Cardiac Death (SCD).
Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, October 27, 2011 at 9 a.m. ET to discuss the Company’s third quarter 2011 financial and operational results.
Aircraft Medical ("Aircraft"), the UK medical devices company, today announces that it has signed an exclusive agreement with Covidien (NYSE: COV), a leading global provider of healthcare products with 2010 revenue of $10.4 billion, and 41,000 employees worldwide.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it will issue its third quarter 2011 financial results at 4:00 p.m. EDT on Wednesday, October 19, 2011. In connection with this announcement, Cubist will host a conference call and live audio webcast (with slides) at 5:00 p.m. EDT the same day to discuss its first quarter financial results, business activities and financial outlook.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, plans to announce its operating results for the quarter ended September 30, 2011 after the market closes on Wednesday, October 19, 2011 and will host a conference call at 5:00 p.m. ET that day to discuss its results.
General Cannabis, Inc. (OTCBB: CANA) (OTCQX: CANA), a technology-based Internet marketing services company, today provided an update on WeedMaps Media's partnership with SC Labs and highlights from the West Coast Cannabis Expo.
Illumina, Inc. (NASDAQ: ILMN) today announced the availability of novel human exome content for three new microarrays, the Infinium HumanExome, OmniExpressExome, and HumanOmni5Exome BeadChips.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at BioCentury NewsMakers in the Biotech IndustryConference on Friday, October 21, 2011 at 1:30 p.m. ET in New York City.
Life Technologies Corporation (NASDAQ: LIFE) today announced the Applied Biosystems QuantStudio™ 12K Flex Real-Time PCR system, a highly versatile genetic analysis instrument that enables cost-effective and efficient interrogation of hundreds of target genes over thousands of samples in a single run.
Metabolix, Inc. (NASDAQ: MBLX), a bioscience company focused on bringing clean, sustainable solutions to the plastics, chemicals and energy industries, announced today that it will be releasing its third quarter financial results after the market close on Tuesday, November 1, 2011.
MMRGlobal, Inc. (OTCBB: MMRF), a leading provider of Personal Health Records, MyEsafeDepositBox storage solutions and electronic document management systems for healthcare professionals, today announced that Mike Finley, Vice President, Worldwide Carrier Relations for Qualcomm, has joined the Company's Board of Directors, the same week The Institute for Health Technology Transformation released that MMRGlobal was selected as the "Stock to Watch" at the annual iHT2 Health Technology Innovation & Investment Forum (http://www.ihealthtran.com/news.html).
Neuralstem, Inc. (NYSE Amex: CUR) announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for patent application 12/418,170 pertaining to a "Spinal Platform and Method for Delivering a Therapeutic Agent to a Spinal Cord Target."
OPKO Health, Inc. (NYSE: OPK) announced that it has completed the sale of its ophthalmic instrumentation business to Optos plc and Optos Inc., a wholly owned subsidiary of Optos plc, a leading and rapidly growing medical technology company engaged in the design, development, manufacture and marketing of devices to image the retina of the eye.
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has launched a podcast series with experience-rich perspectives on topics throughout the clinical development and commercialization lifecycle.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled “5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof.”
Stevia Corp. (OTCBB: STEV) ("Stevia Corp." or the "Company"), a farm management company focused on the economic development of Stevia, the fastest growing product of the alternative sweetening sector, is pleased to announce it has entered into a two-year development agreement with Agro Genesis Pte. Ltd. (www.agro-genesis.com), a leading agribusiness solution provider based in Singapore.